Brian Kenneth Roberts has bought RZLT on 3 days since May 2022

Brian Kenneth Roberts, M.D. is the Chief Medical Officer of Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company focused on transformative therapies for metabolic diseases.( He joined Rezolute in 2017 as Vice President of Clinical Development and a founding member of the management team, advancing to Senior Vice President in 2020 before his promotion to CMO in June 2022, overseeing preclinical, regulatory, and clinical operations.(

Dr. Roberts brings extensive experience in clinical development for metabolic diseases, including prior roles at FibroGen, Inc., where he led the global Phase 3 program for an oral therapy for CKD anemia, contributing to the largest biotech IPO in a decade and global approvals,( and at CymaBay Therapeutics (2007-2012), advancing therapies for diabetes, dyslipidemia, NASH, and gout to proof-of-concept and partnerships.( He holds a B.S. in biochemistry from the University of California, San Diego, an M.D. magna cum laude from Georgetown University, completed residency and fellowship in Internal Medicine and Endocrinology at Stanford University, and serves as an Adjunct Assistant Professor there.( Dr. Roberts is an inventor/author on over 25 patents and publications in endocrinology and metabolism, and as a 10% owner, he recently purchased shares in Rezolute, including 28,000 shares for $47,600 in June 2025 and 2,500 shares for $10,939.(

Written by Perplexity from public sources.